Abstract
Monoclonal antibodies are at the forefront of novel therapeutic strategies for cancer and have made a positive impact on the clinical management of several malignancies. Success in the clinic was originally demonstrated in hematological cancers with the regulatory approval of the anti-CD20 monoclonal antibody rituximab for the treatment of non-Hodgkin’s lymphoma in 1997 and subsequently with the anti-HER2 trastuzumab for the treatment of breast cancer in 1998. Early research and development efforts concentrated on the design of antibodies that selectively target cancer cells or tumor-associated vasculature. In the last decade, two further antibody classes have emerged: checkpoint inhibitors capable of targeting checkpoint molecules on immune cells to activate immune responses against tumors and antibody-drug conjugates, comprising monoclonal antibodies conjugated to toxic payloads to deliver these specifically to tumor cells. A clearer understanding of an antibody’s functional profile may pave the way for identification of the most highly efficacious agents for specific patient groups.
| Original language | English |
|---|---|
| Title of host publication | Principles of Translational Science in Medicine |
| Subtitle of host publication | From Bench to Bedside, Third Edition |
| Editors | Martin Wehling |
| Publisher | Academic Press |
| Chapter | 25 |
| Pages | 329-350 |
| Number of pages | 22 |
| Edition | 3rd |
| ISBN (Electronic) | 9780323999625 |
| ISBN (Print) | 9780128204931 |
| DOIs | |
| Publication status | Published - 15 Jul 2021 |
Keywords
- cancer immunotherapy
- checkpoint inhibitors
- effector functions
- Fab regions
- Fc regions
- IgG, IgE, antibody-drug conjugates (ADCs)
- Monoclonal antibodies
